SCHEMBL1684803

SCHEMBL1684803

CC(=O)c1cccc(Nc2nc(-c3c(C)nc4ccc(Cl)cn34)cs2)c1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.64
MEN1 O00255 9/20 0.57
KMT2A Q03164 9/20 0.57
GAA P10253 4/20 0.56
MAPT P10636 6/20 0.56
ALDH1A1 P00352 5/20 0.56
SMN1; SMN2 Q16637 5/20 0.56
RAB9A P51151 3/20 0.56
NPC1 O15118 2/20 0.56
POLB P06746 2/20 0.56
LMNA P02545 3/20 0.56
HTT P42858 3/20 0.56
KDM4E B2RXH2 3/20 0.56
NPSR1 Q6W5P4 2/20 0.56
AMY1A P0DUB6 1/20 0.56
NR2F2 P24468 1/20 0.56
CACNA1B Q00975 1/20 0.55
APBA1 Q02410 1/20 0.55
KLF5 Q13887 1/20 0.55
MITF O75030 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL18040661 0.99 ALOX5 (0.63) ALOX5MEN1KMT2AGAAMAPT
SCHEMBL1684866 0.89 MEN1 (0.57) ALOX5MEN1KMT2AGAAMAPT
SCHEMBL1684942 0.89 PRKD3 (0.54) ALOX5MEN1KMT2AGAAMAPT
Bromide SCHEMBL18040816 0.88 MEN1 (0.57) ALOX5MEN1KMT2AGAAMAPT
Bromide SCHEMBL18040802 0.88 MAPT (0.54) ALOX5MEN1KMT2AGAAMAPT
SCHEMBL1684679 0.87 MAPT (0.62) ALOX5MEN1KMT2AGAAMAPT
SCHEMBL1684839 0.87 MAPT (0.72) ALOX5MEN1KMT2AGAAMAPT
SCHEMBL2353272 0.87 CACNA1B (0.73) ALOX5MEN1KMT2AGAAMAPT
Bromide SCHEMBL18040717 0.86 MAPT (0.70) ALOX5MEN1KMT2AGAAMAPT
Bromide SCHEMBL18040668 0.86 MAPT (0.61) ALOX5MEN1KMT2AGAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP claimed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US claimed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US claimed
EP-2306836-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2011-04-13 EP claimed
WO-2010002985-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2010-01-07 WO claimed
EP-3111956-B1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2019-05-08 EP disclosed
EP-3111956-A1 BMI 1 PROTEIN EXPRESSION MODULATORS PTC Therapeutics, Inc. (US) 2017-01-04 EP disclosed
EP-2306836-B1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS INC (US) 2016-09-07 EP disclosed
US-8680113-B2 BMI-1 protein expression modulators PTC THERAPEUTICS, INC. (US) 2014-03-25 US disclosed
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS PTC THERAPEUTICS, INC. (US) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190239-A1 BMI-1 PROTEIN EXPRESSION MODULATORS BMI1, CREBBP, BAZ2A ALOX5 4441/4885MEN1 1191/4885KMT2A 156/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.